Deguelin induces the apoptosis of lung squamous cell carcinoma cells through regulating the expression of galectin-1

International Journal of Biological Sciences

Volumn 12, Issue 7, 2016, Pages 850-860

  Yan, Bing ^a   Zhao, Dejian ^a   Yao, Yinan ^a   Bao, Zhang ^a   Lu, Guohua ^a   Zhou, Jianying ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Deguelin; Galectin 1; Lung squamous cell carcinoma

Indexed keywords

DEGUELIN; GALECTIN 1; ROTENONE;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG TUMOR; METABOLISM; MOUSE; NON SMALL CELL LUNG CANCER; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GALECTIN 1; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; REAL-TIME POLYMERASE CHAIN REACTION; ROTENONE; SIGNAL TRANSDUCTION;

EID: 84970965466     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.14773     Document Type: Article

References (50)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65: 87-108.
2. Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. International journal of nanomedicine. 2014; 9: 209-21.
3. Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, et al. Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells. PLoS ONE. 2013; 8: e65113.
4. Liu YP, Lee JJ, Lai TC, Lee CH, Hsiao YW, Chen PS, et al. Suppressive function of low-dose deguelin on the invasion of oral cancer cells by downregulating tumor necrosis factor alpha-induced nuclear factor-kappa B signaling. Head & neck. 2015.
5. Shang HS, Chang JB, Lin JH, Lin JP, Hsu SC, Liu CM, et al. Deguelin inhibits the migration and invasion of U-2 OS human osteosarcoma cells via the inhibition of matrix metalloproteinase-2/-9 in vitro. Molecules. 2014; 19: 16588-608.
6. Boreddy SR, Srivastava SK. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene. 2013; 32: 3980-91.
7. Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, Aggarwal BB. Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. Journal of immunology. 2006; 177: 5612-22.
8. Geeraerts B, Vanhoecke B, Vanden Berghe W, Philippe J, Offner F, Deforce D. Deguelin inhibits expression of IkappaBalpha protein and induces apoptosis of B-CLL cells in vitro. Leukemia. 2007; 21: 1610-8.
9. Kang HW, Kim JM, Cha MY, Jung HC, Song IS, Kim JS. Deguelin, an Akt inhibitor, down-regulates NF-kappaB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Digestive diseases and sciences. 2012; 57: 2873-82.
10. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer research. 2007; 67: 11630-9.
11. Chun KH, Kosmeder JW, 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. Journal of the National Cancer Institute. 2003; 95: 291-302.
12. Murillo G, Salti GI, Kosmeder JW, 2nd, Pezzuto JM, Mehta RG. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. European journal of cancer. 2002; 38: 2446-54.
13. Wang Y, Ma W, Zheng W. Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Molecular and clinical oncology. 2013; 1: 215-9.
14. Nguyen MP, Lee D, Lee SH, Lee HE, Lee HY, Lee YM. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion. Oncotarget. 2015; 6: 16588-600.
15. Suh YA, Kim JH, Sung MA, Boo HJ, Yun HJ, Lee SH, et al. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer letters. 2013; 332: 102-9.
16. Bundela S, Sharma A, Bisen PS. Potential Compounds for Oral Cancer Treatment: Resveratrol, Nimbolide, Lovastatin, Bortezomib, Vorinostat, Berberine, Pterostilbene, Deguelin, Andrographolide, and Colchicine. PLoS One. 2015; 10: e0141719.
17. Hsu YC, Chiang JH, Yu CS, Hsia TC, Wu RS, Lien JC, et al. Antitumor effects of deguelin on H460 human lung cancer cells in vitro and in vivo: Roles of apoptotic cell death and H460 tumor xenografts model. Environmental toxicology. 2015.
18. Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes & cancer. 2011; 2: 261-74.
19. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 2001; 20: 7486-93.
20. Zhou X, Li D, Wang X, Zhang B, Zhu H, Zhao J. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget. 2015; 6: 3111-22.
21. Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai MH, Feng WC, et al. Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer. Molecular & cellular proteomics: MCP. 2015; 14: 1527-45.
22. Manzi M, Bacigalupo ML, Carabias P, Elola MT, Wolfenstein-Todel C, Rabinovich GA, et al. Galectin-1 Controls the Proliferation and Migration of Liver Sinusoidal Endothelial Cells and Their Interaction with Hepatocarcinoma Cells. Journal of cellular physiology. 2015.
23. Tang D, Gao J, Wang S, Yuan Z, Ye N, Chong Y, et al. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36: 5617-26.
24. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, et al. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 4037-47.
25. Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. European journal of cancer. 2012; 48: 1914-21.
26. Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, Tiszlavicz L, et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology. 2005; 69: 167-74.
27. van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. The Journal of pathology. 2001; 193: 80-7.
28. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer treatment reviews. 2014; 40: 307-19.
29. Miao JH, Wang SQ, Zhang MH, Yu FB, Zhang L, Yu ZX, et al. Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway. Oncology reports. 2014; 32: 1497-504.
30. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 2003; 17: 1765-82.
31. Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Treatment of advanced squamous cell carcinoma of the lung: a review. Translational lung cancer research. 2015; 4: 524-32.
32. Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK, Kurie JM. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10: 1074-9.
33. Udeani GO, Gerhauser C, Thomas CF, Moon RC, Kosmeder JW, Kinghorn AD, et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer research. 1997; 57: 3424-8.
34. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. Journal of the National Cancer Institute. 2005; 97: 1695-9.
35. Ji BC, Yu CC, Yang ST, Hsia TC, Yang JS, Lai KC, et al. Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncology reports. 2012; 27: 959-64.
36. Yang YL, Ji C, Bi ZG, Lu CC, Wang R, Gu B, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013; 8: e54736.
37. Lee H, Lee JH, Jung KH, Hong SS. Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncology reports. 2010; 24: 957-63.
38. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006; 16: 137R-57R.
39. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer research. 2013; 73: 1107-17.
40. Barrow H, Rhodes JM, Yu LG. The role of galectins in colorectal cancer progression. International journal of cancer Journal international du cancer. 2011; 129: 1-8.
41. Chow SN, Chen RJ, Chen CH, Chang TC, Chen LC, Lee WJ, et al. Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. European journal of gynaecological oncology. 2010; 31: 55-62.
42. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer research. 2013; 73: 86-96.
43. He XJ, Tao HQ, Hu ZM, Ma YY, Xu J, Wang HJ, et al. Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin beta1. Cancer science. 2014; 105: 1402-10.
44. Masamune A, Satoh M, Hirabayashi J, Kasai K, Satoh K, Shimosegawa T. Galectin-1 induces chemokine production and proliferation in pancreatic stellate cells. American journal of physiology Gastrointestinal and liver physiology. 2006; 290: G729-36.
45. Carlini MJ, Roitman P, Nunez M, Pallotta MG, Boggio G, Smith D, et al. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients. Lung cancer. 2014; 84: 73-8.
46. Chen J, Tang D, Wang S, Li QG, Zhang JR, Li P, et al. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35: 2513-9.
47. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. International journal of cancer Journal international du cancer. 2007; 120: 2331-8.
48. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature reviews Cancer. 2003; 3: 11-22.
49. Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Current topics in microbiology and immunology. 2010; 346: 143-69.
50. Chen Y, Wu Q, Cui GH, Chen YQ, Li R. Deguelin blocks cells survival signal pathways and induces apoptosis of HL-60 cells in vitro. International journal of hematology. 2009; 89: 618-23.